How glutathione affects the growth of triple-negative breast cancer
Impact of extracellular glutathione catabolism on triple-negative breast cancer
This study is looking at how a substance called glutathione, which usually helps protect cells, might actually help triple-negative breast cancer grow, and it hopes to find new ways to treat this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11210736 on NIH RePORTER |
What this research studies
This research investigates the role of extracellular glutathione, a key antioxidant, in the growth of triple-negative breast cancer (TNBC). It aims to understand how glutathione, which is typically thought to work inside cells, may actually promote tumor growth from outside the cancer cells. The study will explore the metabolism of glutathione in the body and how its breakdown products can influence cancer progression. By examining these mechanisms, the research seeks to uncover new therapeutic targets for treating TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with other subtypes of breast cancer or those not diagnosed with breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that inhibit tumor growth in patients with triple-negative breast cancer.
How similar studies have performed: While the role of antioxidants in cancer therapy is being explored, this specific approach focusing on extracellular glutathione in TNBC is relatively novel and has not been extensively tested.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Harris, Isaac Spencer — University of Rochester
- Study coordinator: Harris, Isaac Spencer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.